A carregar...
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dep...
Na minha lista:
| Publicado no: | J Hematol Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4929758/ https://ncbi.nlm.nih.gov/pubmed/27363983 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0283-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|